RenoVate Therapeutics Email Formats

Biotechnology Research • • 1-10 Employees

Key Contacts at RenoVate Therapeutics

Daniel Clayman

Co-Founder

Dorit Omer

Co-Founder, Cto

Company overview

Headquarters	XX
Website	renovate.bio
NAICS	541714
Founded	2022
Employees	1-10

About RenoVate Therapeutics

RenoVate Therapeutics is an early-stage biotechnology company based on the research conducted by Prof. Benjamin Dekel, Head of the Pediatric Stem cell Research Institute and the Director of the Division of Pediatric Nephrology at Sheba Medical Center, Israel. RenoVate is developing regenerative biomolecules aimed to repair and rejuvenate kidneys. The regenerative biomolecules are derived from cells expanded from a patient's own urine using proprietary technology. This groundbreaking IP will ultimately prevent the need for dialysis and kidney transplantations.

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Entry

C-Suite

Founder/Owner

Employees by Department

RenoVate Therapeutics has 4 employees across 2 departments.

Departments

Number of employees

Funding Data

RenoVate Therapeutics has never raised funding before.

Frequently asked questions

RenoVate Therapeutics is located in XX.

RenoVate Therapeutics was founded in 2022, making it 4 years old. The company has established itself as a significant player in its industry over this time.

RenoVate Therapeutics has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contacts at RenoVate Therapeutics

Daniel Clayman

Co-Founder

Dorit Omer

Co-Founder, Cto

4.8

40,000 users